Propanc Biopharma, Inc. (PPCB)
USD 5.5
(-25.98%)
USD 5.5
(-25.98%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 | 1.5 Million USD | -15.46% |
| 2023 | 1.77 Million USD | -10.76% |
| 2022 | 1.99 Million USD | 9.86% |
| 2021 | 1.81 Million USD | -48.14% |
| 2020 | 3.49 Million USD | 33.64% |
| 2019 | 2.61 Million USD | -33.97% |
| 2018 | 3.95 Million USD | -31.01% |
| 2017 | 5.74 Million USD | -16.78% |
| 2016 | 6.89 Million USD | 304.41% |
| 2015 | 1.7 Million USD | 124.06% |
| 2014 | 761.22 Thousand USD | -44.11% |
| 2013 | 1.36 Million USD | -88.25% |
| 2012 | 11.58 Million USD | 418.47% |
| 2011 | 2.23 Million USD | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q2 | 438.06 Thousand USD | 6.83% |
| 2024 Q3 | 416.09 Thousand USD | -5.02% |
| 2024 Q4 | 259.89 Thousand USD | -37.54% |
| 2024 Q1 | 410.07 Thousand USD | 95.64% |
| 2023 FY | 1.77 Million USD | -10.76% |
| 2023 Q1 | 572.83 Thousand USD | -4.4% |
| 2023 Q4 | 209.6 Thousand USD | -45.73% |
| 2023 Q3 | 386.2 Thousand USD | -36.48% |
| 2023 Q2 | 608 Thousand USD | 6.14% |
| 2022 Q3 | 502.18 Thousand USD | 24.47% |
| 2022 FY | 1.99 Million USD | 9.86% |
| 2022 Q4 | 599.19 Thousand USD | 19.32% |
| 2022 Q2 | 403.46 Thousand USD | -16.99% |
| 2022 Q1 | 486.03 Thousand USD | -33.14% |
| 2021 FY | 1.81 Million USD | -48.14% |
| 2021 Q1 | 383.16 Thousand USD | -35.5% |
| 2021 Q3 | 427.95 Thousand USD | 56.13% |
| 2021 Q4 | 726.93 Thousand USD | 69.86% |
| 2021 Q2 | 274.09 Thousand USD | -28.47% |
| 2020 Q3 | 607.16 Thousand USD | -56.12% |
| 2020 Q4 | 594.07 Thousand USD | -2.16% |
| 2020 FY | 3.49 Million USD | 33.64% |
| 2020 Q1 | 909.41 Thousand USD | 8.74% |
| 2020 Q2 | 1.38 Million USD | 52.14% |
| 2019 Q2 | 757.82 Thousand USD | 68.83% |
| 2019 Q3 | 571.72 Thousand USD | -24.56% |
| 2019 Q4 | 836.33 Thousand USD | 46.28% |
| 2019 FY | 2.61 Million USD | -33.97% |
| 2019 Q1 | 448.87 Thousand USD | -12.29% |
| 2018 Q3 | 807.13 Thousand USD | -43.83% |
| 2018 Q2 | 1.43 Million USD | 19.36% |
| 2018 Q1 | 1.2 Million USD | 8.51% |
| 2018 Q4 | 511.75 Thousand USD | -36.6% |
| 2018 FY | 3.95 Million USD | -31.01% |
| 2017 FY | 5.74 Million USD | -16.78% |
| 2017 Q4 | 1.1 Million USD | -28.29% |
| 2017 Q3 | 1.54 Million USD | -18.95% |
| 2017 Q2 | 1.9 Million USD | 62.57% |
| 2017 Q1 | 1.17 Million USD | -66.02% |
| 2016 FY | 6.89 Million USD | 304.41% |
| 2016 Q1 | 1 Million USD | 43.62% |
| 2016 Q2 | 1.14 Million USD | 13.54% |
| 2016 Q3 | 1.29 Million USD | 12.85% |
| 2016 Q4 | 3.45 Million USD | 167.72% |
| 2015 Q1 | 238.13 Thousand USD | 93.79% |
| 2015 Q4 | 701.44 Thousand USD | 35.79% |
| 2015 Q3 | 516.56 Thousand USD | 107.09% |
| 2015 Q2 | 249.44 Thousand USD | 4.75% |
| 2015 FY | 1.7 Million USD | 124.06% |
| 2014 Q3 | 104.31 Thousand USD | -53.73% |
| 2014 FY | 761.22 Thousand USD | -44.11% |
| 2014 Q1 | 308.57 Thousand USD | 62.6% |
| 2014 Q2 | 225.45 Thousand USD | -26.94% |
| 2014 Q4 | 122.88 Thousand USD | 17.8% |
| 2013 Q3 | 229.36 Thousand USD | -48.68% |
| 2013 Q4 | 189.77 Thousand USD | -17.26% |
| 2013 FY | 1.36 Million USD | -88.25% |
| 2013 Q1 | 495.98 Thousand USD | -80.51% |
| 2013 Q2 | 446.89 Thousand USD | -9.9% |
| 2012 Q2 | 2.87 Million USD | -6.34% |
| 2012 Q3 | 3.09 Million USD | 7.49% |
| 2012 Q1 | 3.07 Million USD | 368.87% |
| 2012 FY | 11.58 Million USD | 418.47% |
| 2012 Q4 | 2.54 Million USD | -17.78% |
| 2011 Q3 | 508.49 Thousand USD | 3.28% |
| 2011 FY | 2.23 Million USD | 0.0% |
| 2011 Q4 | 655.63 Thousand USD | 28.94% |
| 2011 Q2 | 492.36 Thousand USD | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | 1.33 Million USD | -12.465% |
| Arch Therapeutics, Inc. | 5.04 Million USD | 70.212% |
| Evofem Biosciences, Inc. | 29.55 Million USD | 94.918% |
| Nascent Biotech, Inc. | 2.22 Million USD | 32.647% |
| Rebus Holdings, Inc. | 664 Thousand USD | -126.19% |
| Santhera Pharmaceuticals Holding AG | 37.25 Million USD | 95.969% |
| Qrons Inc. | 643.67 Thousand USD | -133.331% |
| Adynxx, Inc. | - USD | -Infinity% |
| Neon Bloom, Inc. | 389.56 Thousand USD | -285.531% |
| Northwest Biotherapeutics, Inc. | 57.44 Million USD | 97.385% |
| ProtoKinetix, Incorporated | 415.47 Thousand USD | -261.486% |
| Skye Bioscience, Inc. | 13.54 Million USD | 88.914% |
| Eiger BioPharmaceuticals, Inc. | 86.78 Million USD | 98.269% |
| Nanobac Pharmaceuticals, Incorporated | 4.91 Million USD | 69.461% |
| Institute of Biomedical Research Corp. | 261.72 Thousand USD | -473.844% |
| SQZ Biotechnologies Company | 85.61 Million USD | 98.246% |
| Intellipharmaceutics International Inc. | 2.91 Million USD | 48.499% |
| Mesoblast Limited | 5.9 Million USD | 74.553% |
| Marizyme, Inc. | 19.23 Million USD | 92.194% |
| Genus plc | 147.7 Million USD | 98.983% |
| VioQuest Pharmaceuticals, Inc. | 8.77 Million USD | 82.893% |
| Pharming Group N.V. | 225.49 Million USD | 99.334% |
| Therapeutic Solutions International, Inc. | 2.04 Million USD | 26.69% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -11.953% |
| Nymox Pharmaceutical Corporation | 8.33 Million USD | 81.989% |
| ContraFect Corporation | 56.88 Million USD | 97.36% |
| PsyBio Therapeutics Corp. | 4.4 Million USD | 65.933% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.47 Million USD | -1.565% |
| IMV Inc. | 37.7 Million USD | 96.017% |
| AXIM Biotechnologies, Inc. | 2.79 Million USD | 46.175% |
| MultiCell Technologies, Inc. | 567.42 USD | -264589.119% |
| ONE Bio Corp. | 6.44 Million USD | 76.693% |
| Accustem Sciences Inc. | 3.74 Million USD | 59.911% |
| RVL Pharmaceuticals plc | 85.94 Million USD | 98.252% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 531.96 Thousand USD | -182.332% |
| Q BioMed Inc. | 3.43 Million USD | 56.297% |
| Emmaus Life Sciences, Inc. | 24.71 Million USD | 93.923% |
| Mosaic ImmunoEngineering Inc. | 2.62 Million USD | 42.84% |
| Biomind Labs Inc. | 994.18 Thousand USD | -51.069% |
| American Oriental Bioengineering, Inc. | 99.33 Million USD | 98.488% |
| Provectus Biopharmaceuticals, Inc. | 1.75 Million USD | 14.649% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 6.71 Million USD | 77.644% |
| GlobeStar Therapeutics Corporation | 1.86 Million USD | 19.442% |
| THC Farmaceuticals, Inc. | -25 Thousand USD | 6107.596% |
| Acro Biomedical Co., Ltd. | 16.01 Million USD | 90.619% |
| Curative Biotechnology, Inc. | 1.83 Million USD | 18.157% |
| GB Sciences, Inc. | 1.42 Million USD | -5.73% |
| Alpha Cognition Inc. | 9.7 Million USD | 84.525% |
| HST Global, Inc. | 140.9 Thousand USD | -965.88% |
| CSL Limited | 3.44 Billion USD | 99.956% |
| Wesana Health Holdings Inc. | 1.12 Million USD | -33.513% |
| Halberd Corporation | 74.84 Thousand USD | -1906.76% |
| Enzolytics Inc. | 2.17 Million USD | 31.09% |
| Agentix Corp. | 1.37 Million USD | -9.487% |
| Resverlogix Corp. | 12.71 Million USD | 88.185% |
| Nuo Therapeutics, Inc. | 3.65 Million USD | 58.86% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 1.53 Billion USD | 99.902% |
| Enzon Pharmaceuticals, Inc. | 1.04 Million USD | -43.86% |
| Endonovo Therapeutics, Inc. | 2.4 Million USD | 37.549% |
| RespireRx Pharmaceuticals Inc. | 1.57 Million USD | 4.904% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.4 Million USD | 55.891% |
| AVAX Technologies, Inc. | 7.31 Million USD | 79.455% |
| Zenith Capital Corp. | 8.94 Million USD | 83.206% |
| Genscript Biotech Corporation | 825.34 Million USD | 99.818% |
| Ember Therapeutics, Inc. | 17.42 Thousand USD | -8521.199% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.45 Million USD | 38.831% |
| WPD Pharmaceuticals Inc. | 171.5 Thousand USD | -775.697% |
| Cotinga Pharmaceuticals Inc. | 1.92 Million USD | 21.813% |
| Kadimastem Ltd | 2.41 Million USD | 37.683% |
| Helix BioMedix, Inc. | 1.97 Million USD | 23.84% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 10.86 Million USD | 86.179% |
| BioStem Technologies, Inc. | 22.97 Million USD | 93.463% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 181.48 Thousand USD | -727.561% |
| LadRx Corporation | 3.81 Million USD | 60.599% |
| Cell Source, Inc. | 4.32 Million USD | 65.277% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -62.629% |
| Regen BioPharma, Inc. | 923.51 Thousand USD | -62.629% |
| NovAccess Global Inc. | 2.46 Million USD | 39.115% |
| Affymax, Inc. | 39.38 Million USD | 96.187% |
| Itoco Inc. | 919.14 Thousand USD | -63.402% |
| Rasna Therapeutics, Inc. | 4.23 Million USD | 64.565% |
| Pathfinder Cell Therapy, Inc. | 1.11 Million USD | -34.218% |
| Mobile Lads Corp. | 554.54 Thousand USD | -170.834% |
| CytoDyn Inc. | 18.05 Million USD | 91.683% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 25.16 Thousand USD | -5867.257% |
| NanoSphere Health Sciences Inc. | 220.07 Thousand USD | -582.439% |
| Alseres Pharmaceuticals, Inc. | 1.41 Million USD | -5.783% |
| SYBLEU INC | 160.87 Thousand USD | -833.576% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 1.81 Million USD | 17.311% |
| International Stem Cell Corporation | 5.27 Million USD | 71.506% |
| Bioxytran, Inc. | 3.82 Million USD | 60.685% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 52.64 Thousand USD | -2753.043% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 20.34 Thousand USD | -7282.879% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 36.26 Million USD | 95.859% |
| Adhera Therapeutics, Inc. | 1.61 Million USD | 7.176% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 735.83 Thousand USD | -104.108% |
| Innovation Pharmaceuticals Inc. | 3.11 Million USD | 51.723% |
| Neutra Corp. | 243.82 Thousand USD | -515.984% |
| Windtree Therapeutics, Inc. | 17.45 Million USD | 91.397% |
| PureTech Health plc | 144.59 Million USD | 98.961% |
| Coeptis Therapeutics, Inc. | 20.48 Million USD | 92.67% |
| IXICO plc | 4.7 Million USD | 68.092% |
| IntelGenx Technologies Corp. | 8.79 Million USD | 82.927% |
| Gelesis Holdings, Inc. | 117.74 Million USD | 98.724% |
| CSL Limited | 3.89 Billion USD | 99.961% |
| Cellectis S.A. | 97.32 Million USD | 98.457% |